Artificial Intelligence
Liver Cancer Diagnostics Market Worth $15.95Bn, Globally, by 2028 at 8% CAGR – Exclusive Report by The Insight Partners
New York, April 07, 2022 (GLOBE NEWSWIRE) — The Insight Partners published latest research study on “Liver Cancer Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (Laboratory Tests, Endoscopy, Imaging, Biopsy, and Others) and End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutes, and CRO Laboratories)”, the global liver cancer diagnostics market growth is driven by the rising prevalence of liver cancer and increasing R&D investments in the development of novel diagnostic testing. However, the high cost of technologically advanced liver cancer diagnostic solutions hinders the market growth. The laboratory tests segment held the largest share of the market and held the largest market share of 39.61% in 2021.
Get Exclusive Access to Sample Pages of Liver Cancer Diagnostics Market Size – COVID-19 Impact and Global Analysis with Strategic Insights at: https://www.theinsightpartners.com/sample/TIPRE00003017/
| Report Coverage | Details |
| Market Size Value in | US$ 9.32 Billion in 2021 |
| Market Size Value by | US$ 15.95 Billion by 2028 |
| Growth rate | CAGR of 8.0% from 2021 to 2028. |
| Forecast Period | 2021-2028 |
| Base Year | 2021 |
| No. of Pages | 181 |
| No. Tables | 84 |
| No. of Charts & Figures | 73 |
| Historical data available | Yes |
| Segments covered | Type, and End User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Liver Cancer Diagnostics Market: Competitive Landscape and Key Developments
Perspectum; Illumina, Inc.; Koninklijke Philips N.V.; GE Healthcare; Siemens Healthineers AG; QIAGEN; and F. HOFFMANN-LA ROCHE LTD have implemented various inorganic strategies, such as partnerships and collaborations, which bought dynamic improvements in the liver cancer diagnostics market. Various companies are also adopting organic strategies, such as product launches and expansions, to expand their business and enhance geographic presence. Additionally, acquisitions and partnerships help market players strengthen their customer base and expand the product portfolio.
Place Your Inquiry Before Buying: https://www.theinsightpartners.com/inquiry/TIPRE00003017/
In November 2021, Perspectum partnered with HepQuant to provide seamless delivery of HepQuant’s liver function assessment technology via Perspectum’s Contract Research Organization (CRO) services. The collaboration has enabled pharmaceutical companies sponsoring clinical trials for liver diseases, such as liver cirrhosis, nonalcoholic steatohepatitis (NASH), autoimmune liver diseases, and liver cancer, to receive both imaging and function testing expertise from Perspectum’s Pharma Solutions.
In August 2021, Illumina, Inc. acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission’s ongoing regulatory review. There was no legal impediment to acquiring GRAIL in the US. The decision to make the acquisition and hold the companies separate permits the regulatory processes to proceed while safeguarding the life-saving, pro-competitive benefits of this vertical transaction without the deal expiring.
In June 2021, Koninklijke Philips N.V. partnered with Elekta to advance comprehensive and personalized cancer care through precision oncology solutions. The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy. The cross-portfolio collaboration leveraged company’s capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties’ systems and software in order to drive precision in oncology.
In May 2021, GE Healthcare acquired Zionexa, a France-based in-vivo oncology and neurology biomarker developer, to further develop molecular imaging agents for cancer treatment. As per the the agreement, GE Healthcare got the right to develop and commercialize the Zionexa biomarkers and positron emission tomography (PET) imaging agent, Cerianna (fluoroestradiol F-18).
In April 2021, Siemens Healthineers AG acquired Varian Medical Systems, Inc. to create most comprehensive cancer care portfolio in the industry. The acquisition was previously announced on August 2, 2020. The two companies are building a strategic partnership called EnVision, which sets out to create a digital, diagnostic, and therapeutic ecosystem that includes treatment management.
Connect with Our Research Analyst On: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00003017
In January 2021, Perspectum collaborated with University of Oxford and Hampshire Hospitals NHS Foundation Trust (HHFT) to launch a study to use precision medicine for improving the outcomes for liver cancer patients. This study, in collaboration with leading experts from HHFT, has developed state-of-the-art tools that integrate genetic, radiology, and pathology information to improve the diagnosis and characterisation of tumours.
In May 2019, QIAGEN entered into public private partnership with the UK-based organizations to launch APIS Assay Technologies Ltd. Currently, APIS has three tests in development, including a test for prognostic breast cancer diagnostics. APIS hopes to use the insights gained in oncology to expand its diagnostics services in the areas, such as liver and lung diseases, pharmacogenomics and reproductive diagnostics, with the help of multiple technology platforms, such as PCR and NGS, and a wide range of sample types, from tissue to liquid biopsies.
Global Liver Cancer Diagnostics Market: Key Insights – Future Trends
There are several types of liver cancer in adults, and the two most common types are hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). HCC is the most common form of liver cancer among adults in the US, and ICC is a type of liver cancer that occurs in parts of the bile ducts within the liver. Rising advancements in three-dimensional reconstruction image processing technology transformed liver two-dimensional image data into three-dimensional stereoscopic models, and three-dimensional reconstructed images can be restored to real physical models by 3D printing technology. Further, intuitively exhibiting comprehensive information such as variations of intrahepatic blood arteries in greater accuracy and detail is now possible with computer-generated 3D visualization or 3D printed modeling. Moreover, liver volume computation to surgical navigation is vastly improved due to 3D visualization or 3D printed modelling, which allowed for detailed classification of hepatic vessels and liver segmentation, known as Fang’s segmentation, used in diagnosing and treating primary liver cancer.
According to a multi-center study from China, postoperative liver failure and perioperative mortality rates in patients who used 3D visualization were 0.8% and 0.2%, respectively, significantly lower than those who did not use 3D visualization, as reported in comparative international literature. Moreover, due to the rapid development in computer science in the last several decades, especially in artificial intelligence (AI), concepts like machine learning, deep learning, and big data have been applied in many aspects. Deep learning based on artificial neural networks expands the scope of artificial intelligence in the medical field. The research of Radiomics of deep learning is one of the most popular research fields at present. The study of liver diseases by radiomics will contribute to the early diagnosis and treatment of liver diseases and improve survival and cure rates of liver diseases. Thus, the rising emergence of new technologies will fuel the market’s growth during the forecast period.
Buy Premium Copy of Liver Cancer Diagnostics Market Size, Share, Revenue, Strategic Insights and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00003017/
Liver Cancer Diagnostics Market: Segmental Overview
Based on type, the liver cancer diagnostics market is segmented into laboratory tests, endoscopy, imaging, biopsy, and others. The laboratory tests segment held the largest market share in 2021. Moreover, the same segment is anticipated to register the highest CAGR during the forecast period. The market for the laboratory test segment is further bifurcated into blood tests and biomarkers. The strong preference for laboratory tests due to their correctness and cost-efficiency can be linked to their big market and expansion. Laboratory tests are used to assess high-risk patients and determine therapy options, disease stages, and treatment effects on the patients.
Browse Adjoining Reports:
Liver Cancer Therapeutics Market Forecast to 2028 – Covid-19 Impact and Global Analysis – by Liver Cancer Type ( Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Others ); Therapy ( Targeted Therapy, Immunotherapy, Radiation Therapy, Chemotherapy, Others )
Cancer Screening Technology Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type (Instrument-based Inspection, Platform-based Inspection); Application (Lung Cancer Screening, Breast Cancer Screening, Prostate Cancer Screening, Colorectal Cancer Screening, Blood Cancer Screening, Liver Cancer Screening, Pancreatic Cancer Screening, Skin Cancer Screening, Cervical Cancer Screening), and Geography
Interventional Oncology Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Product (Embolization Devices, Ablation Devices, Support Devices); Procedure (Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization or Selective Internal Radiation Therapy, Transcatheter Arterial Embolization or Bland Embolization); Cancer Type (Liver Cancer, Lung Cancer, Bone Cancer, Kidney Cancer, Other Cancers), and Geography
Interventional Oncology Device Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product Type (Ablation Devices, Embolization Device, Support Devices); Procedure (Thermal Tumor Ablation, Non-thermal Tumor Ablation, Transcatheter Arterial Chemoembolization (TACE), Transcatheter Arterial Radioembolization (TARE) or Selective Internal Radiation Therapy (SIRT), Transcatheter Arterial Embolization (TAE) or Bland Embolization); Cancer Type (Lung cancer, Breast Cancer, Liver Cancer, Kidney Cancer, Prostate Cancer, Others), and Geography
Cancer Treatment Drugs Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Product Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy) ; Application (Blood Cancer, Breast Cancer, Lung Cancer, Stomach Cancer, Colorectal Cancer, Prostate Cancer, Esophagus Cancer, Liver Cancer, Cervical Cancer, Bladder Cancer, Kidney Cancer, Others) and Geography
Cell-Based Immunotherapy Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Therapy (Autologous Cellular Immunotherapy, Chimeric Antigen Receptor (CAR) T-Cell Therapy, Dendritic Cell-based Vaccine Therapy); Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Others)
Tumor Ablation Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Technology (Cryoablation, Radiofrequency (RF) Ablation, Microwave Ablation and Others), Application (Lung Cancer, Liver Cancer, Kidney Cancer, Bone Metastasis and Others), Mode of Treatment (Percutaneous Ablation, Surgical Ablation, Laparoscopic Ablation, Others), and Geography
Generic Oncology Drugs Market to 2027 – Global Analysis and Forecasts by Molecular Type (Large Molecule, Small Molecule); Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, Cervical Cancer, Others), and Geography
Liposomal Doxorubicin Market Forecast to 2028 – Covid-19 Impact and Global Analysis – by Product Type (JandJ (Doxil/Caelyx), Sun Pharma (Lipodox), Teva (Myocet), Others); Application (Bone Sarcoma, Breast Cancer, Endometrial Cancer, Gastric Cancer, Kaposi Sarcoma, Kidney Cancer, Leukemia, Liver Cancer, Multiple Myeloma, Other Applications, Ovarian Cancer)
Hadron Therapy Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Type ( Alpha Particle Beam, Beta Particle Beam, Carbon Ion Beam, Electron Beam, Neutron Beam, Proton Beam ); Application ( Bone and Soft Tissue Cancer, Eye Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Pediatric Cancer, Prostate Cancer, Others ); End User ( Hospitals, Clinics, Research Centers ) and Geography
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/liver-cancer-diagnostics-market
Artificial Intelligence
DeepL announces $300 million investment at $2 billion valuation fueled by global demand for AI language solutions
Index Ventures led heavily oversubscribed round with participation from late-stage investment firms ICONIQ Growth, Teachers’ Venture Growth, and more Rapid enterprise adoption of DeepL has fueled the company’s growth in 60+ global markets for 100,000+ businesses, governments, and other organizationsDeepL’s Language AI Platform for business provides category-leading AI-powered translation and writing solutions COLOGNE, Germany, May 22, 2024 /PRNewswire/ — DeepL, a leading Language AI company, today announced $300 million of investment at a $2 billion valuation. Led by Index Ventures, the heavily oversubscribed round attracted strong support from new investors, who will bring their extensive expertise, connections, and resources to support DeepL’s growth and long-term vision to transform the way companies communicate around the world. Additional late-stage investors, including ICONIQ Growth, Teachers’ Venture Growth, and others, also participated, along with existing investors IVP, Atomico, and WiL.
“We’re approaching an inflection point in the AI boom where businesses who are racing to adopt the technology begin to discern between hype versus solutions that are secure and actually solve real problems in their business,” said Jarek Kutylowski, founder and CEO of DeepL. “This new investment comes during what is on track to be DeepL’s most transformative year yet and is a testament to the crucial role that our Language AI platform has in solving the complex linguistic challenges global companies face today. We’re highly focused on continued growth and innovation to expand our solutions and ensure they remain industry-leading in terms of quality, precision, and security. This will bring us closer to a future where every company, regardless of location, can operate seamlessly on a global scale with our AI.”
The new investment comes during a period of significant growth and momentum for DeepL, which has amassed a customer network of 100,000+ businesses, governments, and other organizations worldwide. This network includes Zendesk, Nikkei, Coursera, and Deutsche Bahn, who rely on its highly accurate and secure enterprise Language AI platform to deliver seamless communication, driving international growth and cost savings. In response to surging demand from global enterprises, DeepL has accelerated its expansion efforts and strategic investments into key markets over the past year. In January 2024, DeepL deepened its commitment to the U.S.—now its third largest market—by opening its first office in the region. The company continues to expand its team in the U.S. to support growing demand.
Within the last 12 months, DeepL has also substantially broadened its product offerings tailored for businesses. In April 2024, the company launched DeepL Write Pro, a writing assistant specifically tailored for business writing, powered by its own proprietary LLM technology. The company also continues to expand the range of languages supported by its platform with the recent additions of Arabic, as well as Korean and Norwegian, bringing its total number of languages to 32.
“DeepL’s runaway success is a bit of an ‘open secret’ in the business community,” said Danny Rimer, who led the investment from Index Ventures. “The company is exceptionally thoughtful about creating cutting-edge AI products that deliver real and immediate value to their customers. Jarek and the rest of the DeepL team are equally research and commercially minded – both of which are key to the company’s success.” Index Ventures is recognized for its investments in highly successful SaaS businesses like Figma, Slack, Wiz, and Scale AI.
Demand for AI solutions among global enterprises is on the rise. A recent IBM study found that 42% are already actively deploying AI and 40% are exploring its potential. Within this rapidly evolving landscape, DeepL is leading the way in applying AI to transform the $67.9 billion language industry, which is projected to grow to $95.3 billion by 2028.
Since its inception in 2017, DeepL has become the Language AI provider of choice for businesses across multiple industries including manufacturing, legal, retail, healthcare, technology, and professional services. The company’s specialized Language AI platform has become a critical investment for global businesses today, addressing a variety of communication challenges ranging from internal communications to customer support and international market expansion. Unlike general-purpose AI systems, DeepL’s cutting-edge translation and writing solutions rely on specialized AI models specifically tuned for language, resulting in more precise translations for a variety of use cases and a reduced risk of hallucinations and misinformation. In business translation and writing, accuracy is paramount, making specialized AI models the most reliable and preferred solution for language challenges.
DeepL’s Language AI platform is also proven to drive significant cost savings and efficiencies. A 2024 Forrester study revealed that the use of DeepL delivered 345% ROI for global companies, reducing translation time by 90% and driving a 50% in workload reduction, underscoring, in our opinion, the power of its platform for businesses looking to grow their revenue and enter new markets faster and at scale.
“At Zendesk we see first hand the power of infusing AI tools into customer experience, and DeepL’s industry-leading translation is a prime example,” said Adrian McDermott, CTO, Zendesk. “The ability to have accurate AI translation allows companies from startups to large enterprises the ability to scale globally, reaching prospects and existing customers in new ways. Zendesk’s open and flexible platform allows for seamless partnerships, and the tangible results we’ve seen so far from joint customers have us looking forward to continued work with DeepL.”
Looking ahead, DeepL will continue to invest in research and product innovation to strengthen its suite of leading AI communication tools for businesses. The company is also doubling down on global market expansion and talent recruitment across multiple areas including AI research, product, engineering, and GTM.
About DeepLDeepL is on a mission to break down language barriers for businesses everywhere. Over 100,000 businesses, governments and other organizations and millions of individuals in 63 global markets trust DeepL’s Language AI platform for human-like translation and better writing. Designed with enterprise security in mind, companies around the world leverage DeepL’s AI solutions that are specifically tuned for language to transform business communications, expand markets and improve productivity. Founded in 2017 by CEO Jaroslaw (Jarek) Kutylowski, DeepL today has over 900 passionate employees and is supported by world-renowned investors including Benchmark, IVP and Index Ventures.
Contact:Sebastian RiesOpeners [email protected]+49 1578 058 8488
Logo – https://mma.prnewswire.com/media/2419636/DeepL_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/deepl-announces-300-million-investment-at-2-billion-valuation-fueled-by-global-demand-for-ai-language-solutions-302153042.html
Artificial Intelligence
Hyundai Motor and Plus Announce Collaboration to Demonstrate First Level 4 Autonomous Fuel Cell Electric Truck in the U.S.
Hyundai Motor and Plus collaboration aims to enhance road safety and freight efficiencies by demonstrating benefits of XCIENT Fuel Cell truck equipped with Plus’s Level 4 autonomous driving softwareHyundai Motor’s Class 8 XCIENT Fuel Cell truck featuring Plus’s Level 4 SuperDrive™ system is on display at the Plus ACT Expo booth (#2044)LAS VEGAS and SEOUL, South Korea, May 22, 2024 /PRNewswire/ — Hyundai Motor Company (Hyundai Motor) and autonomous driving software leader Plus today unveiled the first Level 4 autonomous Class 8 hydrogen fuel cell electric truck in the U.S. at the Advanced Clean Transportation (ACT) Expo, the largest advanced clean transportation technology and fleet event in North America.
A result of the collaboration between Hyundai Motor and Plus, Hyundai Motor’s XCIENT Fuel Cell truck, equipped with Plus SuperDrive™ Level 4 autonomous driving technology, is on display at the Plus ACT Expo booth (#2044).
The Level 4 autonomous XCIENT Fuel Cell truck is undergoing initial autonomous driving assessments in the U.S., making it the first-ever Level 4 self-driving test on a Class 8 fuel cell electric truck to take place in the country. The collaboration seeks to show that autonomous hydrogen fuel cell trucks can help make trucking safer, more efficient, and more sustainable.
“We are excited to showcase our collaboration with Plus to test Level 4 autonomous driving technology with our Class 8 XCIENT Fuel Cell truck,” said Martin Zeilinger, Executive Vice President and Head of Commercial Vehicle Development at Hyundai. “Hyundai Motor has been driving the energy transition paradigm with our advanced fuel cell technologies. By adding autonomous capabilities to our world’s first mass-produced hydrogen-powered XCIENT Fuel Cell truck, Hyundai is looking forward to providing fleets and vehicle operators additional solutions that enhance road safety and freight efficiencies thanks to Plus’s industry-leading autonomous driving technology.”
First introduced in 2020, Hyundai Motor’s XCIENT Fuel Cell truck has conducted commercial operations in eight countries worldwide, establishing a successful track record of real-world applications and technological reliability.
At last year’s ACT Expo, Hyundai introduced XCIENT Fuel Cell tractor, the commercialized Class 8 6×4 fuel cell electric model, powered by two 90kW hydrogen fuel cell systems and a 350kW e-motor, providing a driving range of over 450 miles per charge even when fully loaded.
Plus’s SuperDrive™ solution is being deployed across the U.S., Europe, and Australia. The system uses a combination of cutting-edge sensors, including LiDAR, radar and cameras, to provide surround perception, planning, prediction and self-driving capabilities.
“We are thrilled to collaborate with Hyundai Motor Company on this important initiative to create more sustainable and safe transportation options. A decarbonized future with autonomous hydrogen fuel cell electric trucks that also improve safety and efficiency is one that Plus is proud to support with our cutting-edge autonomous driving technology,” said Shawn Kerrigan, COO and Co-Founder at Plus.
Hyundai Motor and Plus have released a video highlighting their collaboration, which can be seen here: https://www.youtube.com/watch?v=_d19h_v7abo.
About Hyundai Motor Company
More information about Hyundai Motor and its products can be found at: https://www.hyundai.com/worldwide/en/ or Newsroom: Media Hub by Hyundai
About Plus
For more information, visit http://www.plus.ai/.
Photo – https://mma.prnewswire.com/media/2417773/2___Image__Hyundai_Motor_and_Plus_Announce_Collaboration_to_Demonstrate_First_Level_4_Autonomous_Fue.jpg
View original content:https://www.prnewswire.co.uk/news-releases/hyundai-motor-and-plus-announce-collaboration-to-demonstrate-first-level-4-autonomous-fuel-cell-electric-truck-in-the-us-302151236.html
Artificial Intelligence
GIGABYTE Showcases AI and User-Friendly Innovative Technology at COMPUTEX 2024
TAIPEI, May 22, 2024 /PRNewswire/ — GIGABYTE, the world’s leading computer brand, is poised to captivate audiences at this year’s COMPUTEX with its latest offerings. From user-friendly designs to groundbreaking advancements in AI, visitors can expect a truly immersive experience across GIGABYTE and AORUS product lines such as motherboards, graphics cards, gaming monitors, and gaming laptops. As the world enters a new era of AI, GIGABYTE’s presence at COMPUTEX hints at exciting developments in the realm of AI, promising visitors a glimpse into the future of computing.
GIGABYTE will showcase cutting-edge features across its product lineup at COMPUTEX 2024. The AI Laptops including AORUS 17X and AORUS 16X steal the spotlight with the exclusive GIGABYTE AI Nexus, featuring three functions including AI Boost, enhancing performance as per specific scenarios, AI Generator for quick startups with generative AI utilities, and AI Power Gear that intelligently conserves battery life by optimizing power consumption. Additionally, the GIGABYTE GeForce RTX 40 SUPER series graphics cards are engineered to provide intense gaming and reliable AI computing power across a diverse range of applications. Complementing these advancements, the OLED Monitor series such as AORUS CO49DQ, integrates AI algorithms to introduce OLED CARE, including six key features designed to minimize burn-in risks on OLED screens and extend the screen’s lifespan.
In terms of user-friendly designs, GIGABYTE presents innovations like the EZ-Latch and Stealth Design on motherboards, streamlining PC assembly with quick and convenient installations while ensuring a clean appearance through efficient cable management. The LCD Edge View across various components like AORUS GeForce RTX 4080 SUPER MASTER enables real-time monitoring of PC performance and customizable display options. Furthermore, the GIGABYTE Arm Edition gaming monitors are equipped with ergonomic monitor mounts designed to cater to various usage environments from PC gaming, console gaming, to even streaming media, realizing the true 4K entertainment. Within the GIGABYTE OLED Gaming Monitor series, the Tactical Switch feature optimizes gaming by instant switching to a 24-inch size, 1080p resolution with a single click, specifically designed for first-person shooter games.
Additionally, GIGABYTE is proud to showcase multiple Red Dot 2024 award-winning products, including the Z790 AORUS XTREME X, Z790 AORUS MASTER X, Z790 AORUS PRO X, X670E AORUS PRO X motherboards, AORUS FO32U2P, GIGABYTE MO34WQC2 gaming monitors, and AORUS C400 GLASS gaming chassis. For more information, please visit the official GIGABYTE website at: https://bit.ly/GIGABYTE_COMPUTEX_2024
Photo – https://mma.prnewswire.com/media/2415827/GIGABYTE_Showcases_AI_and_User_Friendly_Innovative_Technology_at_COMPUTEX_2024.jpg
View original content:https://www.prnewswire.co.uk/news-releases/gigabyte-showcases-ai-and-user-friendly-innovative-technology-at-computex-2024-302148997.html
-
Artificial Intelligence6 days agoJapan Data Center Market Investment to Reach $14.48 Billion by 2028 – Watch Out Exclusive Insight on Japan & Hong Kong Data Center Market – Arizton
-
Uncategorized5 days agoCoca-Cola: The future is ‘AI meets human ingenuity’
-
Uncategorized7 days ago
Google to roll out AI-generated summaries at top of search engine
-
Artificial Intelligence6 days agoStrava Unveils New Chapter of Accelerated Product Development at Brand’s Flagship Event
-
Artificial Intelligence5 days agoMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
-
Artificial Intelligence6 days agoData Center Colocation Market Worth USD 58.4 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.
-
Artificial Intelligence7 days ago
IBM Expands Qiskit, World’s Most Performant Quantum Software
-
Uncategorized5 days ago
The rise of intelligent automation as a strategic differentiator
